Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Kura Oncology begins trial for AML treatment combination

EditorEmilio Ghigini
Published 26/02/2024, 13:02
© Reuters.
KURA
-

SAN DIEGO - Kura Oncology, Inc. (NASDAQ: NASDAQ:KURA), a clinical-stage biopharmaceutical company, has announced the initiation of a Phase 1 clinical trial, KOMET-008, involving its investigational drug ziftomenib.

The trial is evaluating ziftomenib in combination with other treatments for acute myeloid leukemia (AML) patients with specific genetic mutations.

The study will assess the safety, tolerability, pharmacokinetics, and clinical activity of ziftomenib when used with gilteritinib, FLAG-IDA, or LDAC in patients with relapsed or refractory NPM1-mutant or KMT2A-rearranged AML. The first patient has been dosed in the trial, marking a significant step in the development of this potential new therapy.

Dr. Stephen Dale, Chief Medical Officer of Kura Oncology, highlighted the poor prognosis for AML patients with NPM1-mutant and co-occurring FLT3 mutations, emphasizing the need for an effective treatment. He expressed hope that the combination of ziftomenib and gilteritinib, both oral medications, could offer an attractive treatment option for these patients.

Ziftomenib, a menin inhibitor, targets a protein-protein interaction believed to be a driver of AML with certain genetic alterations. The drug has previously shown promising results in monotherapy and has received Orphan Drug Designation from the U.S. Food and Drug Administration for the treatment of AML.

Kura Oncology is also conducting additional studies to evaluate ziftomenib in combination with standard treatments for various AML patient populations. Preliminary data from a related study, KOMET-007, showed positive results from 20 patients as of January 30, 2024.

AML is a challenging disease with a high unmet need for effective treatments, as current options have limited success, especially in relapsed or refractory cases. The menin pathway is considered crucial in the disease's progression, with NPM1 mutations present in approximately 30% of AML cases and KMT2A rearrangements in about 5-10%.

This news is based on a press release statement from Kura Oncology. The company continues to explore precision medicines for cancer treatment, with a pipeline of small molecule drug candidates targeting various cancer signaling pathways. The ongoing trials and studies are part of Kura's commitment to addressing the unmet needs of AML patients.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.